BEKHEALTH

Diligent Pharma named BEKhealth to its 2026 list of AI-powered patient recruitment providers, highlighting our ability to read structured and unstructured EHR data and surface protocol-eligible patients in seconds. The post 8 AI-Powered Patient Recruitmen

Diligent Pharma named BEKhealth to its 2026 list of site selection and feasibility companies, recognizing our AI-powered patient matching platform and our approach of grounding site selection in real patient data from EHRs rather than self-reported enroll

Provenance is one of four reliability tests for real-world data, and the only one that rarely produces a number, so it rarely gets tested. What data lineage actually requires, and the three questions that reveal whether a partner can document it. The post

ICH M14 took effect in March, and it changes when real-world data source selection has to happen. Feasibility is now an input to study design rather than a step that follows it. Here is what the guidance requires and what to ask data partners during evalu

Every real-world data source looks strong on a slide, yet patient count says nothing about whether the data fits your study. Learn the fitness-for-use framework of relevance and reliability behind research-ready real-world data. The post What Makes Real-W

Speed, accuracy, and trust in real-world evidence are usually a trade-off. A researcher working with the BEKnetwork explains how to get all three without compromising rigor. The post Speed, Accuracy, and Trust in Real-World Evidence: A Researcher's View a

Two decades of investment. Deeper claims databases. Wider EHR networks. And yet a landmark JAMA study found that none of 50 FDA-required confirmatory trials could be emulated using retrospective real-world data. The gap isn't about volume. It's about reac

The use of RWD in clinical trial design has never been higher. Enrollment performance has not improved in step. Nearly 80% of trials miss their original timelines, and one in ten sites enrolls zero patients. Three structural failure modes explain the gap,

The latest Pharma IT outlook highlights that the future of clinical development will be defined by how well we operationalize data. AI, real-world evidence, and smarter infrastructure are no longer future concepts... The post First Analysis: Industry Foru

Eligibility explains who could enroll. Enrollability determines who will. When trials confuse the two, feasibility looks strong and enrollment falls short. The post Why "Eligible Patients" Aren't Always Enrollable Patients appeared first on BEKhealth.